Treatment Considerations in ALK-Positive NSCLC

episode

Conversations in Lung Cancer Research not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Essentials: How to Assess & Improve All Aspects of Your Fitness | Dr. Andy Galpin 35 min · 17 Sep 2026 · Huberman Lab

#502 – Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung 3h 43m · 17 Sep 2026 · Lex Fridman Podcast

September 16, 2026 PC - Sep 16, 2026 1h 50m · 16 Sep 2026 · Fairfax County Planning Commission

Planning Commision 09/16/2026 - Sep 16, 2026 56 min · 16 Sep 2026 · Prince William County Planning Commission

Western Loudoun Rural Uses and Standards PCZOC Ad Hoc Meeting 2 - Sep 16, 2026 4h 45m · 16 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded21 Apr 2023

Publisherfeeds.simplecast.com ↗

Handlerec:1544656

Show notes

In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O’Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014. They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient’s lifestyle.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in